Impact of duration and dose of gonadotrophins on IVF outcomes

Reproductive BioMedicine Online

Volumn 13, Issue 5, 2006, Pages 645-650

  Martin, J Ryan ^a   Mahutte, Neal G ^b   Arici, Aydin ^a   Sakkas, Denny ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Follicular stimulation; Gonadotrophin dosage; IVF outcome

Indexed keywords

CHORIONIC GONADOTROPIN; GONADOTROPIN; LEUPRORELIN; RECOMBINANT FOLLITROPIN;

ADULT; AMPOULE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HUMAN; MAJOR CLINICAL STUDY; NIDATION; OOCYTE; OUTCOME ASSESSMENT; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; OVARY HYPERSTIMULATION; PREGNANCY RATE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT DURATION;

EID: 33751095170     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60654-2     Document Type: Article

References (22)

1. Abu-Heija AT, Yates RW, Barrett T et al. 1995 A comparison of two starting doses of human menopausal gonadotrophin for follicle stimulation in unselected patients for in-vitro fertilization. Human Reproduction 10, 801-803.
2. Balasch J, Fabregues F, Creus M et al. 2001 Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Human Reproduction 16, 652-656.
3. Centers for Disease Control and Prevention 2002 Assisted Reproductive Technology Success Rates, National Summary and Fertility Clinic Reports. Department of Health and Human Services.
4. Cramer DW, Liberman RF, Powers D et al. 2000 Recent trends in assisted reproductive techniques and associated outcomes. Obstetrics and Gynecology 95, 61-66.
5. Dorn C 2005 FSH: What is the highest dose for ovarian stimulation that makes sense on an evidence-based level? Reproductive BioMedicine Online 11, 555-561.
6. Evert JP, Van Santbrink EJP, Fauser BCJM 1997 Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistent anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down regimens. Journal of Clinical Endocrinology and Metabolism 82, 3597-3602.
7. Fauser BCJM, Devroey P, Yen SS et al. 1999 Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Human Reproduction 14, 2681-2686.
8. Hock DL, Louie H, Sheldon RM et al. 1998 The need to step up the gonadotrophin dosage in the stimulation phase of IVF treatment predicts poor outcome. Journal of Assisted Reproduction and Genetics 15, 427-430.
9. Karande VC, Jones GS, Veeck LL et al. 1990 High dose follicle stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in-vitro fertilization outcome in low-responder patients. Fertility and Sterility 53, 486-489.
10. Keck C 2005 Factors influencing response to ovarian stimulation. Reproductive BioMedicine Online 11, 562-569.
11. Kerin JF, Warnes GM, Quinn P et al. 1984 Endocrinology of ovarian stimulation for in-vitro fertilization. Journal of Obstetrics and Gynecology 24, 121-124.
12. Khalaf Y, El-Toukhy T, Taylor A, Braude P 2002 Increasing gonadotrophin dose in the course of an in-vitro fertilization cycle does not rectify an initial poor response. European Journal of Obstetrics and Gynecology and Reproductive Biology 103, 146-154.
13. Land JA, Yarmolinskaya MI, Dumoulin JC et al. 1996 High dose human menopausal gonadotropin stimulation in poor responders does not improve in-vitro fertilization outcomes. Fertility and Sterility 65, 961-965.
14. Ludwig M, Keck C 2005. Recombinant gonadotropins in reproductive medicine: gold standard for ovarian stimulation therapy in the 21st century. Reproductive BioMedicine Online 11, 535-536.
15. Manzi DL, Thornton KL, Scott LB et al.1994 The value of increasing the dose of human menopausal gonadotropins in women who initially demonstrate a poor response. Fertility and Sterility 62, 251-256.
16. Menken J, Trussell J, Larsen U 1986 Age and Infertility. Science 233, 1389-1394.
17. Out HJ, Braat DD, Lintsen BM et al. 2000 Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Human Reproduction 15, 29-35.
18. Ron-El R, Raziel A, Strassburger D et al. 2000 Outcome of assisted reproductive technology in women over the age of 41. Fertility and Sterility 74, 471-475.
19. Sharma V, Allgar V, Rajkhowa M 2002 Factors influencing the cumulative conception rate and discontinuation of in-vitro fertilization treatment for infertility. Fertility and Sterility 78, 40-46.
20. Steptoe PC, Edwards RG 1978 Birth after the reimplantation of a human embryo. Lancet 2, 366.
21. Templeton A, Morris JK, Parslow W 1996 Factors that affect outcome of in-vitro fertilization treatment. Lancet 348, 1402-1406.
22. Van Hooff MH, Alberda AT, Huisman GJ et al. 1993 Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Human Reproduction 8, 369-373.